Vanguard Capital Management
ARCT icon

Vanguard Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Vanguard Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.49M Buy
1,114,956
+7,936
+0.7% +$62.6K ﹤0.01% 2965
2026
Q1 		$8.55M Buy
+1,107,020
New +$8.08M ﹤0.01% 2816

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vanguard Capital Management's ARCT Position: Q2 2026 in Review

Vanguard Capital Management increased its Arcturus Therapeutics (ARCT) stake by 0.72% in Q2 2026, buying an estimated $62.6K and bringing the position to 1,114,956 shares worth $7.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2965.

Vanguard Capital Management first reported a position in ARCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.55M in Q1 2026. 133 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Vanguard Capital Management held 1,114,956 shares of Arcturus Therapeutics worth $7.49M as of Q2 2026.
  • Vanguard Capital Management bought 7,936 Arcturus Therapeutics shares in Q2 2026, an estimated $62.6K.
  • Arcturus Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2965 holding.
  • Vanguard Capital Management first reported a position in Arcturus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Arcturus Therapeutics position peaked at $8.55M in Q1 2026.
  • 133 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.